Agilent Technologiesの空売り状況は、投資家がAgilent Technologiesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Agilent Technologies (NYSE:A) 株価情報, 空売り情報

Agilent Technologies

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

Agilent Technologies Inc

Ancient8 - United States Dollar

Alcoa Corp

Alternative Access First Priority CLO Bond ETF

Aareal Bank AG Registered Shares

Aareal Bank AG DR

Goldman Sachs Physical Gold ETF Shares

AAX Token

ASIA BROADBAND INC by Asia Broadband, Inc.

Asia Broadband Inc

Aareal Bank AG

ABERDEEN INTL INC by Aberdeen International Inc.

Aberdeen International Inc

ARES ACQUISITION CORP CL A ORD SHS

Double-A Chain

AAC TECHS HLDGS INC ORD by AAC Technologies Holdings Inc

AAC Technologies Holdings Inc

AAC TECHS HLDGS UNSP/ADR by AAC Technologies Holdings Inc

Artius II Acquisition Inc. - Class A Ordinary Shares

Artius II Acquisition Inc

Artius II Acquisition Inc. - Rights

ATA Creativity Global - American Depositary Shares, each representing two common shares

ATA Creativity Global

Armada Acquisition Corp I

Armada Acquisition Corp I Units (1 Ord & 1/2 War)

Armada Acquisition Corp I Warrants (13/08/2026)

AMER COMMERCE SOLTNS INC by American Commerce Solutions, Inc.

American Commerce Solutions Inc

Ares Acquisition Corporation II Class A Ordinary Shares

Ares Acquisition Corp II

Ares Acquisition Corporation II Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant

Ares Acquisition Corporation II Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50

AURORA SOLAR TECHNOLOGIES by Aurora Solar Technologies Inc.

Aurora Solar Technologies Inc

AADI BIOSCIENCE INC

AdvisorShares Dorsey Wright ADR ETF

Altair Resources Inc

Airtel Africa PLC

SILVER47 EXPL CORP by Silver47 Exploration Corp.

ALL AMERICAN GOLD CORP by All American Gold Corp.

All American Gold Corp

AFTERMATH SILVER LTD ORD by Aftermath Silver Ltd.

Aftermath Silver Ltd

AMERICA GREAT HEALTH by America Great Health

America Great Health

AIA Group Ltd

AFRICAN AGRI HLDGS INC by African Agriculture Holdings Inc.

African Agriculture Holdings Inc

African Agriculture Holdings Inc Warrants (06/12/2028)

ASTRA AGRO LESTR UNSP/ADR by Astra Agro Lestari TBK

PT Astra Agro Lestari Tbk

Asahi Co Ltd

ALABAMA AIRCRAFT INDUS by Alabama Aircraft Industries, Inc.

Alabama Aircraft Industries Inc

Arlington Asset Investment Corp 6.000% Sr Nt 08/01/2026

American Aires Inc Ordinary Shares

AMERICAN AIRES INC by American Aires Inc.

American Aires Inc

AAK AB

American Airlines Group, Inc. - Common Stock

American Airlines Group Inc

AALBERTS INDUS NV ORD by A. Alberts Industries

Aalberts NV

AA Mission Acquisition Corp. Class A Ordinary Shares

AA Mission Acquisition Corp

AA Mission Acquisition Corp. Units, each consisting of one Class A Ordinary Share and one-half of one redeemable warrant

AA Mission Acquisition Corp. Warrants, each whole warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share

ATLAS MARA CO NVEST ORD by Atlas Mara Co Nvest Ltd.

Atlas Mara Ltd

Altisource Asset Management Corp Com

ALTISOURCE ASSET MGMT by Altisource Asset Management Corp

Altisource Asset Management Corp

Atlantic American Corporation - Common Stock

Atlantic American Corp

Acadian Asset Management Inc. Common Stock

Acadian Asset Management Inc

ALMADEX MINERALS LTD by Almadex Minerals Ltd.

Almadex Minerals Ltd

ARMADA MERCANTILE LTD by Armada Mercantile Ltd.

Armada Mercantile Ltd

Aaron's Co Inc (The) Com

Aroundtown SA

Applied Optoelectronics, Inc. - Common Stock

Applied Optoelectronics Inc

AAON Inc

Advance Auto Parts Inc

GraniteShares 2x Long AAPL Daily ETF

Direxion Daily AAPL Bear 1X Shares

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group International

ASCENTAGE PHARMA GROUP INTL DS

APPLE ISPORTS GROUP INC by Apple iSports Group Inc.

Apple iSports Group Inc

AAP Inc

Apple Inc

SHL Telemedicine Ltd Innovator Equity Defined Protection ETF - 2 Yr to April 2026

ALL AMERICAN PET CO INC by All American Pet Company, Inc.

Kuora Inc

Direxion Daily AAPL Bull 2X Shares

Roundhill ETF Trust Roundhill AAPL WeeklyPay ETF

ETF Opportunities Trust T-Rex 2X Long Apple Daily Target ETF

Kurv Yield Premium Strategy Apple (AAPL) ETF

ANTIAGING QNTUM LGN A by Antiaging Quantum Living Inc.

Antiaging Quantum Living Inc

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics Inc

AIRTEL AFRICA PLC ADR by Airtel Africa Plc

ABERDEEN ASIAN SMALLR COS by Aberdeen Asian Smaller Companies Investment Trust Plc

Aberdeen Asian Smaller Co Investment Trust Plc

AMERICA'S SUPPLIERS INC by America's Suppliers, Inc.

ASIA AIR SURVEY CO LTD by ASIA AIR SURVEY CO LTD.

Asia Air Survey Co Ltd

AGASSI SPORTS ENTERTMT by Agassi Sports Entertainment Corp.

Agassi Sports Entertainment Corp

Atlantic Sapphire ASA Ordinary Shares

ATLANTIC SAPPHIRE AS by Atlantic Sapphire ASA

Atlantic Sapphire ASA

American Assets Trust Inc

AUTOSCOPE TECHS CORP by Autoscope Technologies Corporation

Autoscope Technologies Corp

ATI Airtest Technologies Inc

ATI AIRTEST TECHS INC by ATI Airtest Technologies Inc.

AMG CAP TR II 5.15% CONV by AMG Capital Trust II

ADAPTIVE AD SYSTEMS INC by Adaptive Ad Systems, Inc.

Adaptive Ad Systems Inc

ALMADEN MINERALS LTD COM

ALMADEN MINERALS LTD by Almaden Minerals Ltd.

Almaden Minerals Ltd

Allied Gold Corp

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said no to O&#8217;Reilly Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>). 
&#8220;You want to buy the one that's not going to stock split, which is AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>),&#8221;<a href="https://www.benzinga.com/quote/ORLY/earnings"> he added.</a>
Adding support to his view, O&#8217;Reilly Automotive posted first-quarter earnings of $9.35 per share on April 23, missing market estimates of $9.94 per share. The company's quarterly sales came in at $4.14 billion versus expectations of $4.17 billion.
AutoZone has outperformed the market over the past 15 years by 10.81% on an annualized basis producing an average annual return of 22.06%. Currently, the company has a market capitalization of $62.8 billion.
See Also: <a href="https://www.benzinga.com/insights/news/25/05/45322871/heres-how-much-100-invested-in-autozone-15-years-ago-would-be-worth-today">Here&#8217;s How Much $100 Invested In AutoZone 15 Years Ago Would Be Worth Today</a>
Cramer said the last couple quarters have been weak for ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>). He recommended buying Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) over ASML.
Supporting his view, ASML Holding reported a first-quarter sales miss on April 16. Sequentially, revenue declined by 16.75% from €9.3 billion in the fourth quarter.
Cramer said no to Onto Innovation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>), adding that he likes Agilent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>).
Onto Innovation issued second-quarter guidance below estimates on May 8. The company sees second-quarter adjusted EPS of $1.21-$1.35, versus market estimates of $1.50. The company expects sales of $240.00 million —$260.00 million, versus projections of $269.10 million.
The Mad Money host said no to Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>). &#8220;Engineering and construction, we're going to buy letter J, we'll buy Jacobs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>),&#8221; he added.
UBS analyst Steven Fisher maintained Fluor with a buy rating on May 7 and lowered the price target from $49 to $48.
Price Action:
<ul class="wp-block-list">
<li>ASML shares fell 1.4% to settle at $758.36 on Thursday.</li>
<li>O'Reilly Automotive shares rose 3.4% to close at $1,370.13 during the session.</li>
<li>Onto Innovation shares fell 5.8% to settle at $98.04.</li>
<li>Fluor shares fell 0.5% to close at $38.53 on Thursday.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45435278/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yields-7">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

News

Markets

Media

Trading Ideas

ASML

LRCX

ONTO

ORLY

Jim Cramer Prefers AutoZone Over Rival: 'Buy The One That's Not Going To Stock Split'

Agilent Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) short percent of float has risen 17.01% since its last report. The company recently reported that it has 4.32 million shares sold short, which is 1.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Agilent Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747152025_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Agilent Technologies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Agilent Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Agilent Technologies's peer group average for short interest as a percentage of float is 7.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Agilent Technologies?

Jefferies analyst Brandon Couillard maintains Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) with a Hold and lowers the price target from $135 to $116.

Price Target

Analyst Ratings

Jefferies Maintains Hold on Agilent Technologies, Lowers Price Target to $116

5 analysts have expressed a variety of opinions on Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $142.0, a high estimate of $159.00, and a low estimate of $115.00. A decline of 3.92% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1744912862_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Agilent Technologies's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $135.00&#x7C;$155.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $115.00&#x7C;$138.00 &#x7C; 
&#x7C;Catherine Schulte &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $159.00&#x7C;$161.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $145.00&#x7C;$135.00 &#x7C; 
&#x7C;Derik De Bruin &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $156.00&#x7C;$150.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Agilent Technologies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Agilent Technologies compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Agilent Technologies's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/A/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Agilent Technologies analyst ratings.</a>
<h2>Delving into Agilent Technologies's Background</h2>
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
<h3>Agilent Technologies: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3M period, Agilent Technologies showcased positive performance, achieving a revenue growth rate of 1.39% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Agilent Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.92% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Agilent Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of 5.33%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.68%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.56, Agilent Technologies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Agilent Technologies: 5 Analysts Share Their Views

Wells Fargo analyst Brandon Couillard maintains Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) with a Overweight and lowers the price target from $155 to $135.

Wells Fargo Maintains Overweight on Agilent Technologies, Lowers Price Target to $135

European certification for PD-L1 IHC 22C3 pharmDx to help gastric or GEJ adenocarcinoma patients for KEYTRUDA&#xAE; therapy
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agilent.com&amp;esheet=54239505&amp;newsitemid=20250417981526&amp;lan=en-US&amp;anchor=Agilent+Technologies+Inc.&amp;index=1&amp;md5=189415f0603bad84f35737c63c76e8f5">Agilent Technologies Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) today announced its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agilent.com%2Fen-us%2Fproduct%2Fpharmdx%2Fpd-l1-ihc-22c3-pharmdx%2Fpd-l1-ihc-22c3-pharmdx-product-page&amp;esheet=54239505&amp;newsitemid=20250417981526&amp;lan=en-US&amp;anchor=PD-L1+IHC+22C3+pharmDx&amp;index=2&amp;md5=21cf51e6b3279e302118ed584b1c2264">PD-L1 IHC 22C3 pharmDx</a> (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.keytrudahcp.com%2F&amp;esheet=54239505&amp;newsitemid=20250417981526&amp;lan=en-US&amp;anchor=KEYTRUDA%26%23174%3B&amp;index=3&amp;md5=0c3043ee2dca3cb48ea79aaa891d2630">KEYTRUDA&#xAE;</a> (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution. KEYTRUDA is an anti-PD-1 therapy developed by <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.merck.com%2F&amp;esheet=54239505&amp;newsitemid=20250417981526&amp;lan=en-US&amp;anchor=Merck&amp;index=4&amp;md5=d752f5b3ee034d4f80798653f8ac39a7">Merck</a> (known as MSD outside the United States and Canada).
In addition to gastric or GEJ adenocarcinoma, PD-L1 IHC 22C3 pharmDx is IVDR certified as an aid in identifying non-small cell lung cancer (NSCLC), urothelial carcinoma, esophageal cancer, head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), and cervical cancer patients for treatment with KEYTRUDA. Consequently, PD-L1 IHC 22C3 pharmDx is labeled for seven cancer indications and is the only IVDR-certified CDx to identify gastric and GEJ adenocarcinoma patients for treatment with KEYTRUDA.

Agilent Technologies Gets European Certification For PD-L1 IHC 22C3 pharmDx To Help Gastric Or GEJ Adenocarcinoma Patients for KEYTRUDA Therapy

Barclays analyst Luke Sergott maintains Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) with a Equal-Weight and lowers the price target from $138 to $115.

Barclays Maintains Equal-Weight on Agilent Technologies, Lowers Price Target to $115

Disclosed in the latest SEC filing, a significant insider purchase on March 18, involves Mala Anand, Director at Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>).
What Happened: Anand's recent move, as outlined in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001090872/000112760225009719//Archives/edgar/data/1090872/000112760225009719/0001127602-25-009719-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, involves purchasing 1,819 shares of Agilent Technologies. The total transaction value is $220,426.
During Tuesday's morning session, Agilent Technologies shares up by 0.04%, currently priced at $122.54.
<h3>Get to Know Agilent Technologies Better</h3>
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
<h3>Key Indicators: Agilent Technologies's Financial Health</h3>
Revenue Growth: Agilent Technologies's revenue growth over a period of 3 months has been noteworthy. As of 31 January, 2025, the company achieved a revenue growth rate of approximately 1.39%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 53.48%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Agilent Technologies's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 1.12.
</li>
</ul>
Debt Management: Agilent Technologies's debt-to-equity ratio is below the industry average. With a ratio of 0.56, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 28.09 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 5.42, Agilent Technologies's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an impressive EV/EBITDA ratio of 19.86, Agilent Technologies demonstrates exemplary market valuation, surpassing industry averages.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Exploring Key Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001090872">Check Out The Full List Of Agilent Technologies's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Director At Agilent Technologies Buys $220K of Stock

A notable insider purchase on March 18, was reported by Otis W Brawley, Board Member at Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), based on the most recent SEC filing.
What Happened: Brawley's recent move, as outlined in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001090872/000112760225009720//Archives/edgar/data/1090872/000112760225009720/0001127602-25-009720-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, involves purchasing 2,631 shares of Agilent Technologies. The total transaction value is $318,824.
Agilent Technologies shares are trading up 0.04% at $122.54 at the time of this writing on Tuesday morning.
<h3>Unveiling the Story Behind Agilent Technologies</h3>
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
<h3>Agilent Technologies: Delving into Financials</h3>
Revenue Growth: Over the 3 months period, Agilent Technologies showcased positive performance, achieving a revenue growth rate of 1.39% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 53.48%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Agilent Technologies exhibits below-average bottom-line performance with a current EPS of 1.12.
</li>
</ul>
Debt Management: Agilent Technologies's debt-to-equity ratio is below the industry average. With a ratio of 0.56, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 28.09 is lower than the industry average, implying a discounted valuation for Agilent Technologies's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 5.42 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Agilent Technologies's EV/EBITDA ratio stands at 19.86, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001090872">Check Out The Full List Of Agilent Technologies's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Agilent Technologies Board Member Trades $318K In Company Stock

In a recent SEC filing, it was revealed that HEIDI FIELDS, Board Member at Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), made a noteworthy insider purchase on March 18,.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001090872/000112760225009722//Archives/edgar/data/1090872/000112760225009722/0001127602-25-009722-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that FIELDS purchased 1,819 shares of Agilent Technologies. The total transaction amounted to $220,426. 
As of Tuesday morning, Agilent Technologies shares are up by 0.04%, currently priced at $122.54.
<h3>Get to Know Agilent Technologies Better</h3>
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
<h3>Unraveling the Financial Story of Agilent Technologies</h3>
Revenue Growth: Agilent Technologies displayed positive results in 3 months. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 1.39%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 53.48%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Agilent Technologies's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 1.12.
</li>
</ul>
Debt Management: Agilent Technologies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.56.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: Agilent Technologies's P/E ratio of 28.09 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 5.42, Agilent Technologies's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Agilent Technologies's EV/EBITDA ratio stands at 19.86, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001090872">Check Out The Full List Of Agilent Technologies's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Agilent Technologies Board Member Trades $220K In Company Stock

On March 18, Dr. Podolsky, Director at Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) executed a significant insider buy, as disclosed in the latest SEC filing.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001090872/000112760225009723//Archives/edgar/data/1090872/000112760225009723/0001127602-25-009723-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Podolsky increased their investment in Agilent Technologies by purchasing 1,819 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $220,426.
Tracking the Tuesday's morning session, Agilent Technologies shares are trading at $122.49, showing a down of 0.0%.
<h3>All You Need to Know About Agilent Technologies</h3>
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
<h3>Agilent Technologies: A Financial Overview</h3>
Revenue Growth: Agilent Technologies displayed positive results in 3 months. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 1.39%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 53.48%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Agilent Technologies's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 1.12.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.56, Agilent Technologies adopts a prudent financial strategy, indicating a balanced approach to debt management.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 28.09 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 5.42 is above industry norms, reflecting an elevated valuation for Agilent Technologies's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Agilent Technologies's EV/EBITDA ratio stands at 19.86, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001090872">Check Out The Full List Of Agilent Technologies's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Director Of Agilent Technologies Purchased $220K In Stock

In a recent SEC filing, it was revealed that Sue Rataj, Board Member at Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), made a noteworthy insider purchase on March 18,.
What Happened: Rataj made a significant move by purchasing 1,819 shares of Agilent Technologies as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001090872/000112760225009724//Archives/edgar/data/1090872/000112760225009724/0001127602-25-009724-index.htm">U.S. Securities and Exchange Commission</a>. The transaction's total worth stands at $220,426.
Monitoring the market, Agilent Technologies's shares down by 0.0% at $122.49 during Tuesday's morning.
<h3>Unveiling the Story Behind Agilent Technologies</h3>
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
<h3>Agilent Technologies: Financial Performance Dissected</h3>
Positive Revenue Trend: Examining Agilent Technologies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.39% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 53.48%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Agilent Technologies's EPS reflects a decline, falling below the industry average with a current EPS of 1.12.
</li>
</ul>
Debt Management: Agilent Technologies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.56.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Agilent Technologies's P/E ratio of 28.09 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 5.42 is above industry norms, reflecting an elevated valuation for Agilent Technologies's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Agilent Technologies's EV/EBITDA ratio, surpassing industry averages at 19.86, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001090872">Check Out The Full List Of Agilent Technologies's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sue Rataj Boosts Confidence With $220K Purchase Of Agilent Technologies Stock

Dr. Scangos, Director at Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), reported an insider buy on March 18, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001090872/000112760225009725//Archives/edgar/data/1090872/000112760225009725/0001127602-25-009725-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Scangos purchased 1,819 shares of Agilent Technologies. The total transaction amounted to $220,426. 
Tracking the Tuesday's morning session, Agilent Technologies shares are trading at $122.49, showing a down of 0.0%.
<h3>Unveiling the Story Behind Agilent Technologies</h3>
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
<h3>Financial Insights: Agilent Technologies</h3>
Revenue Growth: Agilent Technologies displayed positive results in 3 months. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 1.39%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: With a high gross margin of 53.48%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Agilent Technologies exhibits below-average bottom-line performance with a current EPS of 1.12.
</li>
</ul>
Debt Management: Agilent Technologies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.56.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 28.09 is lower than the industry average, implying a discounted valuation for Agilent Technologies's stock.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 5.42 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 19.86, Agilent Technologies demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001090872">Check Out The Full List Of Agilent Technologies's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Director Of Agilent Technologies Makes $220K Buy

Disclosed in the latest SEC filing, a significant insider purchase on March 18, involves DOW WILSON, Director at Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>).
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001090872/000112760225009726//Archives/edgar/data/1090872/000112760225009726/0001127602-25-009726-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, WILSON increased their investment in Agilent Technologies by purchasing 1,819 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $220,426.
Monitoring the market, Agilent Technologies's shares up by 0.04% at $122.54 during Tuesday's morning.
<h3>Unveiling the Story Behind Agilent Technologies</h3>
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
<h3>Agilent Technologies's Financial Performance</h3>
Revenue Growth: Agilent Technologies displayed positive results in 3 months. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 1.39%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: With a high gross margin of 53.48%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Agilent Technologies exhibits below-average bottom-line performance with a current EPS of 1.12.
</li>
</ul>
Debt Management: Agilent Technologies's debt-to-equity ratio is below the industry average at 0.56, reflecting a lower dependency on debt financing and a more conservative financial approach.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: Agilent Technologies's P/E ratio of 28.09 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 5.42 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Agilent Technologies's EV/EBITDA ratio stands at 19.86, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001090872">Check Out The Full List Of Agilent Technologies's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DOW WILSON Boosts Confidence With $220K Purchase Of Agilent Technologies Stock

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agilent.com&amp;esheet=54221636&amp;newsitemid=20250310422488&amp;lan=en-US&amp;anchor=Agilent+Technologies+Inc.&amp;index=1&amp;md5=50a85d0a34fe29942381dfb2eefc68af">Agilent Technologies Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) today announced its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agilent.com%2Fen%2Fproduct%2Fpharmdx%2Fpd-l1-ihc-28-8-pharmdx%2Fpd-l1-ihc-28-8-pharmdx-for-autostainer-link-48-153940&amp;esheet=54221636&amp;newsitemid=20250310422488&amp;lan=en-US&amp;anchor=PD-L1+IHC+28-8+pharmDx&amp;index=2&amp;md5=72c49e2091ba654aa1fc5cd98448661f">PD-L1 IHC 28-8 pharmDx</a> kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.agilent.com%2Fen%2Fproduct%2Fautostainer-link-solution-for-ihc%2Fautostainer-link-48%2Fautostainer-link-48-75845&amp;esheet=54221636&amp;newsitemid=20250310422488&amp;lan=en-US&amp;anchor=Agilent+Autostainer+Link+48&amp;index=3&amp;md5=7be86c60dabca2090227a31e606801cc">Agilent Autostainer Link 48</a> advanced staining solution.
Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accounting for over two million new cases in 2020 and an estimated 1.77 million deaths each year, and malignant melanoma accounting for over 324,000 new cases in 2020 and over 57,000 deaths each year2. PD-L1 is a critical biomarker for potential response to anti-PD-1 therapies, which are revolutionizing the treatment of cancer. Pathology labs play an important role in informing treatment decisions.
When used in conjunction with the PD-L1 IHC 28-8 pharmDx as a companion test, in the European Union: (a) resectable NSCLC patients with PD-L1 expression ≥1% and at high risk of recurrence may be eligible for treatment with Bristol Myers Squibb's OPDIVO&#xAE; (nivolumab) in combination with platinum based chemotherapy; and (b) patients 12 years of age and older with tumor cell PD-L1 expression &lt; 1% that have previously untreated advanced (metastatic or unresectable) melanoma may be eligible for treatment with Bristol Myers Squibb's Opdualag&#x2122; (nivolumab and relatlimab).
PD-L1 IHC 28-8 pharmDx is the only clinically validated test for identifying patients for these treatments; these two new indications will aid pathologists, in conjunction with oncologists, in selecting appropriate treatment options, offering hope for patients diagnosed with these cancers. IVDR compliance certification further enhances the confidence of patients, consumers, and healthcare professionals in the EU by demonstrating that these medical devices can be safely relied upon as part of the diagnostic workflow.

Biotech

General

Agilent PD-L1 IHC 28-8 PharmDx Receives EU IVDR Certification As A Companion Diagnostic Test For Non-small Cell Lung Cancer And Melanoma Indications

David Kostin, the Chief U.S. Equity Strategist of Goldman Sachs, has revised his earnings growth forecast, citing a weaker economic outlook, and highlighted a shift in market trends.
What Happened: On CNBC&#8217;s &#8216;Squawk on the Street&#8217;, Kostin discussed his revised earnings growth forecast and market trends. Initially projected at 11%, the earnings growth forecast for 2025 has now been adjusted to 9%. 
Despite this, Kostin maintains that the earnings growth for 2026 remains at 7%, unchanged. He also stated that the S&amp;P 500 year-end target remains at 6500, suggesting an 11% gain from current levels.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Goldman Sachs&#039; Kostin: We&#039;re revising EPS growth forecast lower, but healthcare poses opportunity" width="500" height="281" src="https://www.youtube.com/embed/Pn9ySR9ygao?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Kostin also noted a shift in investment strategy, with investors moving from &#8220;excitement&#8221; (cyclicals) to &#8220;boredom&#8221;&nbsp;(defensive stocks) amid tariff&nbsp;uncertainties. He identified healthcare and consumer staples as preferred sectors for their stability and less sensitivity to the ongoing trade war. He also named&nbsp;Thermo Fisher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) and Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) as strong investment options. 
Furthermore, he notes a shift in focus from AI infrastructure and hyperscalers to software companies that would be leveraging AI to amplify their revenues, for instance, MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>). 
According to Kostin, uncertainty around tariffs makes forecasting difficult, but models suggest&nbsp;earnings will be impacted through unit volumes and margins. The strategist estimated that a 5% increase in tariffs&nbsp;could reduce earnings growth by&nbsp;1-2%.
SEE ALSO: <a href="https://www.benzinga.com/general/space/25/03/44102170/spacex-scraps-starship-flight-test-on-monday-too-many-question-marks-about-this-flight-says-ceo-elon-musk">SpaceX Scraps Starship Flight Test On Monday: &#8216;Too Many Question Marks About This Flight&#8230;,&#8217; Says CEO Elon Musk</a>
Why It Matters: This shift in investment strategy is noteworthy, considering that institutional investors were bullish on technology and financials during the fourth quarter of 2024. Investors were seen <a href="https://www.benzinga.com/markets/equities/25/02/43878703/institutional-investors-load-up-on-technology-and-financial-stocks-in-q4-while-reducing-positions-in-healthcare-sector-amid-political-uncertainty">pulling back</a> from the healthcare sector, which Kostin now identifies as a preferred sector. Even Warren Buffet&#8216;s Berkshire Hathaway trimmed its stake in healthcare provider DaVita Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), bringing down the ownership to 45%.
These market shifts and Kostin&#8217;s revised forecast underline the uncertainties in the current economic climate but also highlight potential&nbsp;opportunities in defensive sectors and&nbsp;AI-driven businesses. That being said, Kostin expects the falling bond yields to offset some tariff effects, potentially benefiting the economy. He summed up by saying that GDP growth is the primary driver of earnings, with interest rates and inflation playing secondary roles.
The S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) climbed 1.12% to close at 5,842.63 on Wednesday after President Donald Trump pushed back auto tariffs on Canada and Mexico by one month.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/25/03/44159766/us-indicts-12-chinese-nationals-over-alleged-global-hacking-operation-targeting-critics-been-paying-hackers-for-hire-to-inflict-digital-harm-on-americans">US Indicts 12 Chinese Nationals Over Alleged Global Hacking Operation Targeting Critics: &#8216;&#8230;Been Paying Hackers-For-Hire To Inflict Digital Harm On Americans&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Goldman Sachs Cuts Earnings Growth Outlook, Sees Investors Move From 'Excitement' To 'Boredom'

Agilent Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) short percent of float has fallen 8.53% since its last report. The company recently reported that it has 2.97 million shares sold short, which is 1.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.01 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Agilent Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741095045_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Agilent Technologies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Agilent Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Agilent Technologies's peer group average for short interest as a percentage of float is 5.52%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

WIIM

Agilent Technologies shares are trading lower after the company issued FY25 adjusted EPS and Q2 guidance below estimates.

During the last three months, 6 analysts shared their evaluations of Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Agilent Technologies and provided 12-month price targets. The average target is $151.67, accompanied by a high estimate of $159.00 and a low estimate of $145.00. Marking an increase of 2.13%, the current average surpasses the previous average price target of $148.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1740661239_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Agilent Technologies among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$159.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$145.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$156.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$145.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$157.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Agilent Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Agilent Technologies compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Agilent Technologies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Agilent Technologies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/A/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Agilent Technologies analyst ratings.</a>
<h2>Discovering Agilent Technologies: A Closer Look</h2>
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
<h3>Agilent Technologies's Economic Impact: An Analysis</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Agilent Technologies showcased positive performance, achieving a revenue growth rate of 0.77% as of 31 October, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Agilent Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.63% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Agilent Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of 5.95%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Agilent Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.07% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.57, Agilent Technologies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Agilent Technologies Through 6 Analysts

Baird analyst Catherine Schulte maintains Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) with a Outperform and lowers the price target from $161 to $159.

Baird Maintains Outperform on Agilent Technologies, Lowers Price Target to $159

Press Releases

Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Smackover Lithium's South West Arkansas Project Receives Special Designation as a Priority Transparency Critical Mineral Project From the Trump Administration

Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

Smackover Lithium's South West Arkansas Project Receives Unanimous Vote of Approval to Establish the Phase I Brine Production Unit from the Arkansas Oil and Gas Commission

Comments

Agilent Technologies

空売り

Agilent Technologies (NYSE:A) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル